Phreesia, Inc. (NYSE:PHR) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Phreesia, Inc. (NYSE:PHR) by 144.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,716 shares of the company’s stock after buying an additional 86,040 shares during the quarter. JPMorgan Chase & Co.’s holdings in Phreesia were worth $3,666,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Phreesia in the 4th quarter worth approximately $30,000. BankPlus Trust Department bought a new stake in shares of Phreesia in the 4th quarter worth $34,000. Swiss National Bank raised its position in Phreesia by 1.3% in the fourth quarter. Swiss National Bank now owns 107,900 shares of the company’s stock worth $2,715,000 after acquiring an additional 1,400 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Phreesia by 9.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 22,445 shares of the company’s stock worth $565,000 after acquiring an additional 2,008 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Phreesia by 154.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company’s stock worth $89,000 after purchasing an additional 2,090 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP David Linetsky sold 4,499 shares of the firm’s stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $23.73, for a total transaction of $106,761.27. Following the completion of the transaction, the senior vice president now owns 217,239 shares in the company, valued at $5,155,081.47. This trade represents a 2.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Evan Roberts sold 1,845 shares of the business’s stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total transaction of $43,929.45. Following the completion of the sale, the chief operating officer now owns 774,807 shares in the company, valued at $18,448,154.67. This represents a 0.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 177,526 shares of company stock worth $4,908,117 in the last quarter. 5.80% of the stock is currently owned by company insiders.

Phreesia Trading Up 0.1 %

Shares of PHR stock opened at $23.92 on Monday. The business’s 50 day moving average is $26.07 and its two-hundred day moving average is $24.32. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a market cap of $1.41 billion, a PE ratio of -16.27 and a beta of 0.82.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Citigroup raised their price target on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Canaccord Genuity Group boosted their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, March 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia currently has an average rating of “Buy” and an average target price of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.